Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

Published 2020 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
Authors
Keywords
SARS-CoV-2, COVID 19, Baricitinib, Novel Corona Virus
Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 55, Issue 5, Pages 105967
Publisher
Elsevier BV
Online
2020-04-04
DOI
10.1016/j.ijantimicag.2020.105967

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.